

Lignée ORGAPRED N°HN-041

Le MIAOU (**M**inimal **I**nformation **A**bout an **O**rganoid and its **U**se):

Eléments descriptifs permettant à l'homme de l'art de reproduire une expérience de fabrication, de caractérisation et d'étude fonctionnelle d'organoïdes

Le MIAOU sert à identifier les informations présentes (la réponse Oui/Non est la plus importante) et à évaluer la qualité de leur description pour la reproductibilité.

A) SOURCE MATERIAL MATERIEL SOURCE

| | |
|---|-----|
| Informed consent obtained Consentement adapté au but de la recherche | Yes |
| Collection declaration Déclaration de collection- CODECOH* | Yes |
| Descriptors: gender, age, anatomical region, diagnostic, viral statut Descriptif : genre, âge, région anatomique, diagnostic, statut viral | Yes |
| Clinical data on the patient Tableau clinique du patient | Yes |

* : gestion de la COnservation D'Éléments du COrps Humain

Primary cell of patient (and healthy subjects) and tumors Cellule primaire de patient (et sujets sains) et tumeurs

| | |
|--|--|
| Genetic identity at arrival (example: DNA sequence, snips, digital PCR, STR, CGH array) Identité génétique à réception | Yes, STR on tumor and organoid sample for quality control |
| Genetic quality control (example : Karyotype, STR, digital PCR) Contrôle de qualité génétique | Yes, STR on tumor and organoid sample for quality control |
| Functional quality (example: differentiation test for pluripotency of iPSCs, permeability tests for intestinal epithelial cells...) Qualité fonctionnelle | Yes, organoid establishment |
| Cell identity after X passages identité cellulaire après X passages | STR analysis on tumor DNA and on organoid DNA at passage 9. |
| Cell type marker (example : marker name, detection method, target value) Marqueur de type cellulaire | IHC specific markers on tumor fragment: p53 / p40 / p63 / p16 / Ki67 |
| Number of passages at arrival Nombre de passages à la réception | 0, cells directly obtained from patient's tumor |
| Number of possible or required passages before genesis of organoids Nombre de passages possibles ou requis avant genèse des organoïdes | 0, considered established at passage 3 and above |
| Storage conditions Protocole de conservation | Between 100 and 1000k cells in 2 mL cryovials, resuspended in 1000 µL in freezing solution (10% DMSO, 90% FBS) and frozen gradually decreasing temperature |

Lignée ORGAPRED N°HN-041

| | |
|---|--|
| | (1°C/min in CoolCell) to -80°C before long-term storage at -196°C. |
| Mutations if genetic disease Mutations si maladie génétique | Mutation status of 19 major genes frequently mutated in HNSCC available. |
| Contamination tests (mycoplasma, bacteriological, fungal) Tests contamination | Absence of bacterial or fungal contamination Absence of Mycoplasma (biochemical test) |
| Method of tissue dissociation (production of single-cell material or tissue substructures - example: intestinal crypt) Méthode de dissociation du tissu | 1h enzymatic and mechanical dissociation of tumor fragments with Tumor Dissociation Kit, human (Miltenyi) and 100 µm filtration. |

Storage conditions of the lines or cells Conditions de conservation des lignées ou cellules

| | |
|---|---|
| Master banks, (description of protocols, drift control) Banques mères | BRC of the BACLESSE Centre, NF S96-900 certified |
| Daughter banks (description of protocols, drift control) Banques filles.... | No |
| Storage: freezing and thawing protocol Conservation : protocole de congélation et de décongélation | Freezing: between 100 and 1000k cells in 2 mL cryovials, resuspended in 1000 µL in Recovery Cell Culture Freezing Medium (Gibco) and frozen gradually decreasing temperature (1°C/min in CoolCell) to -80°C before long-term storage at -150°C. Thawing: Fast thawing at 37°C, transfer in fresh culture media before centrifugation and matrix seeding. |
| Storage modalities Modalités de conservation | Long-term storage at -150°C. |

B) MANUFACTURING OF THE ORGANIDS FABRICATION DE L'ORGANOIDE

Culture conditions of cells Conditions de culture des cellules

| | |
|---|---|
| Composition of culture media, nature, origin and quantities of supplements used (e.g. glucose, serum, antibiotics, growth factors etc.) Composition des milieux | Culture in an enriched medium [Advanced DMEM (Gibco) supplemented with 100 UI/mL of penicillin and streptomycin (Gibco), 1% GlutaMAX (Gibco), 1X B27 (Gibco), 10 mM Nicotinamide (Sigma-Aldrich), 1.25 mM N-Acetyl-L-Cysteine (Sigma-Aldrich), 100 µg/mL Primocin (InvivoGen), 10 µM Y27632 (Interchim), 10 ng/mL FGF-10 (PeproTech), 500 nM A-83-01 (PeproTech), 50 ng/mL EGF (PeproTech), 5 ng/mL FGF-basic (PeproTech), 1 µM PGE2 (PeproTech), 1 µM Forskolin (PeproTech), 0,3 µM CHIR99021 (Biogems), 50% Wnt3a/RSPO3/Noggin-conditioned medium |
|---|---|

Lignée ORGAPRED N°HN-041

| | |
|---|--|
| | (L-WRN, ATCC), and 10% RSPO1-conditioned medium (Cultrex HA-R-Spondin-1-Fc 293T, Amsbio)]. |
| Nature and treatment of the supports Nature et traitement des supports | 24-well plate Costar: culture treated 6-well plate Nunc: culture treated, Nunclon Delta |
| Seeding conditions Conditions d'ensemencement | 10 000 to 15 000 cells per matrix drop (mix of 70% BME2 and 30% culture media v/v) |
| Frequency of media changes Fréquence des changements de milieu | Twice a week |
| CO ₂ / O ₂ Concentration | Ambient O ₂ and 5% CO ₂ |

Generation of organoids (3D): specificities Génération des organoïdes (3D) : spécificités

Matrix culture *Culture en matrice*

| | |
|---|--|
| Nature of the matrix (matrigel, hydrogels, hyaluronic acid, human decellularized matrix etc.) Nature de la matrice | Cultrex Reduced Growth Factor Basement Membrane Extract, Type 2 |
| Matrix concentration Concentration de la matrice | 70% matrix in 30% media (v/v) |
| Preparation method (temperature, polymerization time, drop or layer structure, etc.) Modalité de préparation | 50 µL drop of matrix and 30 minutes polymerization at 37°C |
| Seeding density per matrix volume unit Densité d'ensemencement | 10 000 to 15 000 cells per matrix drop |
| Volume and number of drops of matrix per unit area in the culture medium | 50 µL drop per well in 24-well plate, 10 drops of 50 µL per well in 6-well plate |
| Amount of medium depending on the size of the well Quantité de milieu en fonction de la taille du puits | 24-well plate: 500µL 6-well plate : 2000µL |
| Matrix dissociation method for organoid recovery Méthode de dissociation de la matrice pour la récupération des organoïdes | Mechanical dissociation using cold Advanced DMEM media (Gibco) supplemented with 100 UI/mL of penicillin and streptomycin (Gibco), 1% GlutaMAX (Gibco), 1% BSA (Panreac) |
| Method of dissociation of organoids for their expansion Méthode de dissociation des organoïdes pour leur expansion | Enzymatic dissociation using TrypLE Express Enzyme (1X) solution, 5-15 minutes incubation at 37°C with gentle agitation every 5 minutes, cold Adv DMEM media (1% BSA, see above) is then add to stop the reaction before centrifugation, numeration and seeding. |

Culture including multiple cell types *Culture incluant de multiples types cellulaires*

| | |
|---|------|
| Sequence of co-culturing and adaptation of co-culture media Séquence des mises en co-culture | N.A. |
| Proportion of cell types Proportion des types cellulaires | N.A. |

Lignée ORGAPRED N°HN-041

C) ORGANOID CHARACTERIZATION CARACTÉRISATION DES ORGANOIDES

The detailed characterization is project dependent, however some standards emerge

| | |
|---|---|
| <i>Morphology</i> <i>Structure</i> | |
| Appearance, size, shape [circularity, tubularity, regularity of contour (budding)] Aspect, taille, forme | Round organoids with defined contours |
| Opacity/réfringency Opacité/réfringence | Opaque |
| Intra and inter-organoid homogeneity Homogénéité | Heterogeneity in shape and size Heterogeneous expression of some IHC markers |
| Expected morphological, architectural and ultrastructural features, organization of cell types (identity, proportions, distribution) Particularités morphologiques | N.A. |

| | |
|---|--|
| <i>Molecular Characterisation</i> <i>Caractérisation moléculaire</i> | |
| Elements of genomics, transcriptomics, metabolomics, proteomics, Eléments de génomique, transcriptomique, métabolomique, protéomique | voir la fiche RIBBON de ce modèle disponible sur https://ribbon.unicaen.fr |
| Expected specific molecular markers, epigenetic characteristics Marqueurs moléculaires | IHC specific markers on organoids: p53 / p40 / p63 / p16 / Ki67 |

| | |
|---|---|
| <i>Function</i> <i>Fonction</i> | |
| Qualitative and (if possible) quantitative functional characteristic Caractéristique fonctionnelle | N.A. |
| Response to treatments (pharmacological, chemical, physical, hormonal...) the treatment protocol, and evaluation (quantitative or qualitative) of the response are described Réponse aux traitements | <p>Protocol: when PDTO reached the size of 75–150 μm in diameter, they were collected and resuspended in PDTO treatment medium (PDTO culture medium lacking primocin, Y-27,632 and N-acetylcysteine) with 2% BME2. 200 PDTO per well were seeded in 100 μL in white, clear-bottom 96-well plates (Greiner) previously coated with a 1:1 mixture of organoid treatment medium and BME2.</p> <p>For radiotherapy response assays, PDTO were irradiated in microtubes using the CellRad irradiator (FAXITRON Bioptics) prior</p> |

Lignée ORGAPRED N°HN-041

| | |
|--|---|
| | <p>to plating, and medium was replaced after 5 days.</p> <p>For chemotherapy response assays, drugs were prepared in 2% BME2/organoid treatment medium and added 1 hour after PDTO plating.</p> <p>PDTO morphology was monitored using IncuCyte S3 (Sartorius). After 7 days (chemotherapy) or 10 days (radiotherapy), ATP levels were quantified using CellTiter-Glo 3D assay (Promega), and luminescence was measured with the GloMax reader (Promega).</p> <p>Cell viability values were normalized to control. Two independent biological replicates were realized in most cases and treatment sensitivity was determined based on the earliest available passage of each PDTO model.</p> <p><u>Evaluation of treatment response for:</u> Cisplatin = resistant Radiotherapy = resistant</p> |
|--|---|

| | |
|---|--|
| <i>Traceability, organoid drift</i> <i>Traçabilité, dérive des organoïdes</i> | |
| Traceability of components (batches, suppliers etc.. environments, complements) Traçabilité des composants | Yes, traceability of every components (batches number, expiration dates ...) |
| Traceability of conditioned media (drift of cells used for conditioning, control of lines as for those at the origin of the organoid), control of at least one of the growth factors) Traçabilité des milieux conditionnés | Traceability of every components (batches number, expiration dates ...) used for conditioned media production. No systematic growth factors quantification in conditioned medium. |
| Drift criteria (morphological, structural, functional, molecular....) specific to each organoid. Specify indices if applicable Critères de dérive | Morphological, response to treatments, IHC markers, STR |
| Robustness criterion (same starting cells, same organoid). Specify indices if applicable Critère de robustesse | No |

Lignée ORGAPRED N°HN-041

D) USE OF ORGANOIDS UTILISATION DES ORGANOIDES

Organoid for basic research *Organoïde en recherche fondamentale*

| | |
|--|----|
| | No |
|--|----|

Organoid in preclinical research (pharmacology, toxicology, ...) *Organoïde en recherche préclinique (pharmacologie, toxicologie, ...)*

| | |
|--|--|
| Functional similarity criterion between the organoid and the mimicked organ (battery of controls to be performed with target values) Similarité fonctionnelle | Patient clinical data are available to assess concordance with organoid-based tests. |
| Number of usable passages Applicable for: Preclinical development of a drug candidate (IND file) using organoids Nombre de passages exploitables | More than 10 |
| Number of usable passages Applicable for: Definition of predictive signatures of responses (companion test) Nombre de passages exploitables | More than 10 |
| Number of usable passages Applicable for : Validation of a care protocol (specific patient) on a cohort: choice of a therapy Validation d'un Protocole de soin | To be defined |

Organoid in clinic (personalized, predictive and regenerative medicine, transplantation)

Organoïde en clinique

| | |
|---|----|
| GMP certification, total traceability of the components, qualification of the components for Domain 1: Care protocol (specific patient) (validation of the protocol of use of the organoid for the orientation of the therapeutic choice) - Criterion of similarity between the organoid and the biopsy Certification GMP | No |
| GMP certification, total traceability of components, qualification of components for Domain 2: Use in regenerative medicine (same as cell and tissue therapies) - Functionality criteria, safety (Derivation of biological material and evaluation of the risk of cancer) Certification GMP | No |